US FDA: Carcinogenic Potency Categorization Approach for Nitrosamine Impurities
Recommendation

20 October 2026
Copenhagen, Denmark
An ECA Course prior to the 29th APIC/CEFIC Global GMP & Regulatory API Conference
In January 2025, the US FDA has published in its newsroom on the CDER website the article called "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach". It is structured in the following chapters and passages:
- Background
- Materials and Methods
- Results
A) α-Hydrogen features in the format "n,n" where the lowest number of hydrogens is listed first
B) Deactivating features
C) Activating features - Discussion
- Other resources
The article clearly explains the historical background of developing and establishing the "Carcinogenic Potency Categorization Approach (CPCA)" and provides an overview of deactivating and activating features in a listed order.
The complete article "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach" can be checked in the newsroom of CDER's website.
Related GMP News
12.10.2026EMA Reports inconsistent Progress in International API Inspection Cooperation
23.09.2026FDA Warning Letter: serious GMP Deficiencies at a Chinese API Manufacturer
16.09.2026PFAS restriction: Commission highlights Importance of critical Medical Applications
16.09.2026IPEC: Updated Qualification-Guide published
09.09.2026IPEC: New Stability Guide for Excipients Published


